Farrukh T. Awan

9.1k total citations · 1 hit paper
199 papers, 3.7k citations indexed

About

Farrukh T. Awan is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Farrukh T. Awan has authored 199 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Genetics, 93 papers in Pathology and Forensic Medicine and 62 papers in Hematology. Recurrent topics in Farrukh T. Awan's work include Chronic Lymphocytic Leukemia Research (127 papers), Lymphoma Diagnosis and Treatment (92 papers) and Chronic Myeloid Leukemia Treatments (36 papers). Farrukh T. Awan is often cited by papers focused on Chronic Lymphocytic Leukemia Research (127 papers), Lymphoma Diagnosis and Treatment (92 papers) and Chronic Myeloid Leukemia Treatments (36 papers). Farrukh T. Awan collaborates with scholars based in United States, France and Germany. Farrukh T. Awan's co-authors include John C. Byrd, Jennifer A. Woyach, Mehdi Hamadani, Jeffrey A. Jones, Kami J. Maddocks, Leslie A. Andritsos, Kerry A. Rogers, Natarajan Muthusamy, Joseph M. Flynn and Carolyn Cheney and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Farrukh T. Awan

184 papers receiving 3.7k citations

Hit Papers

Ibrutinib treatment improves T cell number and function i... 2017 2026 2020 2023 2017 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ibrutinib treatment improves T cell number and function in CLL patients
    2017 288 citations Jeffrey A. Jones, Leslie A. Andritsos et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Farrukh T. Awan United States 33 2.0k 1.6k 1.3k 976 935 199 3.7k
Preetesh Jain United States 32 2.2k 1.1× 1.5k 1.0× 846 0.7× 1.0k 1.0× 1.4k 1.5× 181 3.7k
Julio Delgado Spain 35 1.6k 0.8× 1.3k 0.8× 939 0.7× 1.0k 1.0× 1.1k 1.2× 195 3.6k
Stefano Molica Italy 31 1.9k 0.9× 1.4k 0.9× 980 0.8× 726 0.7× 671 0.7× 170 3.0k
David Westerman Australia 27 1.4k 0.7× 1.4k 0.9× 545 0.4× 776 0.8× 732 0.8× 125 2.8k
Stephen Opat Australia 25 1.4k 0.7× 1.7k 1.1× 562 0.4× 980 1.0× 570 0.6× 158 2.7k
Simon Rule United Kingdom 30 1.6k 0.8× 2.4k 1.5× 519 0.4× 1.7k 1.7× 593 0.6× 155 3.4k
Paul M. Barr United States 32 2.5k 1.3× 2.6k 1.6× 951 0.8× 1.2k 1.2× 848 0.9× 188 3.9k
Sergej Konoplev United States 35 1.2k 0.6× 964 0.6× 1.1k 0.9× 1.4k 1.4× 2.2k 2.4× 154 4.6k
Jeffrey Matous United States 29 1.6k 0.8× 2.3k 1.4× 831 0.7× 1.8k 1.9× 1.2k 1.3× 128 4.2k
Marzia Varettoni Italy 25 1.7k 0.8× 1.2k 0.8× 604 0.5× 790 0.8× 1.3k 1.4× 98 2.8k

Countries citing papers authored by Farrukh T. Awan

Since Specialization
Citations

This map shows the geographic impact of Farrukh T. Awan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Farrukh T. Awan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Farrukh T. Awan more than expected).

Fields of papers citing papers by Farrukh T. Awan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Farrukh T. Awan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Farrukh T. Awan. The network helps show where Farrukh T. Awan may publish in the future.

Co-authorship network of co-authors of Farrukh T. Awan

This figure shows the co-authorship network connecting the top 25 collaborators of Farrukh T. Awan. A scholar is included among the top collaborators of Farrukh T. Awan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Farrukh T. Awan. Farrukh T. Awan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Anderson, Mary Ann, Farrukh T. Awan, Leanne Berkahn, et al.. (2025). Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors. Internal Medicine Journal. 55(9). 1556–1569. 1 indexed citations
2.
3.
Patel, Manish R., Michael Tees, Farrukh T. Awan, et al.. (2024). Abstract PO-009: AC676 a BTK Chimeric Degrader: Phase 1 study in patients with B-cell Malignancies. Blood Cancer Discovery. 5(3_Supplement). PO–9. 3 indexed citations
4.
Ahmed, Gulrayz, Anikó Szabó, Mazyar Shadman, et al.. (2024). CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Advances. 8(13). 3528–3531. 2 indexed citations
5.
Pophali, Priyanka A., Joshua Fein, Kwang Woo Ahn, et al.. (2024). CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma. Blood Advances. 8(20). 5290–5296. 6 indexed citations
6.
Awan, Farrukh T., et al.. (2023). The Total Lifetime Cost of Treating Patients (Pts) with CLL in the United States (US). Blood. 142(Supplement 1). 2330–2330.
7.
Patel, A., Radhika Kainthla, Farrukh T. Awan, et al.. (2022). Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting. Neuro-Oncology Practice. 9(3). 183–192. 4 indexed citations
8.
Munshi, Pashna N., Yue Chen, Kwang Woo Ahn, et al.. (2022). Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. Transplantation and Cellular Therapy. 28(8). 487.e1–487.e7. 11 indexed citations
9.
Bhat, Seema A., Marilly Palettas, Tracy Wiczer, et al.. (2022). Ventricular arrhythmias and sudden death events following acalabrutinib initiation. Blood. 140(20). 2142–2145. 46 indexed citations
10.
Thangavadivel, Shanmugapriya, Qiuhong Zhao, Narendranath Epperla, et al.. (2020). Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clinical Cancer Research. 26(23). 6187–6195. 3 indexed citations
11.
Awan, Farrukh T., Anna Schuh, Jennifer R. Brown, et al.. (2019). Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Advances. 3(9). 1553–1562. 144 indexed citations
12.
13.
Rogers, Kerry A., Luay Mousa, Qiuhong Zhao, et al.. (2017). Incidence and Type of Opportunistic Infections during Ibrutinib Treatment at a Single Academic Center. Blood. 130(Suppl_1). 830–830. 23 indexed citations
14.
Awan, Farrukh T., Shanmugapriya Thangavadivel, David M. Weiss, et al.. (2017). A Phase 2 Trial of Early Intervention with Ibrutinib in Patients with Asymptomatic, High-Risk CLL. Blood. 130. 1748–1748. 1 indexed citations
15.
16.
Robak, Tadeusz, Andrzej Hellmann, Janusz Kłoczko, et al.. (2016). Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 176(4). 618–628. 30 indexed citations
17.
Kharfan‐Dabaja, Mohamed A., et al.. (2016). Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Practice & Research Clinical Haematology. 29(1). 54–66. 4 indexed citations
18.
Brown, Jennifer R., Matthew S. Davids, Jordi Rodón, et al.. (2015). Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma. Clinical Cancer Research. 21(14). 3160–3169. 45 indexed citations
19.
Awan, Farrukh T., Samith T. Kochuparambil, David L. DeRemer, et al.. (2012). Plerixafor Salvage Is Safe and Effective in Hard-to-Mobilize Patients Undergoing Chemotherapy and Filgrastim-Based Peripheral Blood Progenitor Cell Mobilization. Journal of Oncology. 2012. 1–5. 11 indexed citations
20.
Andritsos, Leslie A., Amy J. Johnson, Gerard Lozanski, et al.. (2008). Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 26(15). 2519–2525. 117 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Preetesh Jain Breakdown of academic impact, for papers by Julio Delgado Breakdown of academic impact, for papers by Stefano Molica Breakdown of academic impact, for papers by David Westerman Breakdown of academic impact, for papers by Stephen Opat Breakdown of academic impact, for papers by Simon Rule Breakdown of academic impact, for papers by Paul M. Barr Breakdown of academic impact, for papers by Sergej Konoplev Breakdown of academic impact, for papers by Jeffrey Matous Breakdown of academic impact, for papers by Marzia Varettoni
Rankless by CCL
2026